← Back to Search

Corticosteroid

A: Triamcinolone acetonide for Vitiligo

Phase 2
Waitlist Available
Led By Harvey Lui, MD, FRCPC
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-5 weeks after each treatment session
Awards & highlights

Study Summary

This trial is studying the effectiveness of corticosteroid injections to treat vitiligo, a skin condition causing white patches and marks. The effects & safety of the injections are being compared over 4-6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-5 weeks after each treatment session
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-5 weeks after each treatment session for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assessment of the degree of repigmentation based on the modified VASI score for each half. We will consider the treatment successful if there was ≥50% change in modified VASI score from baseline.
Secondary outcome measures
Assessment of side effects in each half including atrophy, telangiectasia, hyperpigmentation and hypopigmentation using a severity scale as follows: 0=none, 1=mild, 2=moderate, 3=severe.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: A: Triamcinolone acetonideActive Control1 Intervention
Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
Group II: B: Normal salinePlacebo Group1 Intervention
Bacteriostatic normal saline will injected into one half of the vitiligo patch.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,413 Previous Clinical Trials
2,466,943 Total Patients Enrolled
4 Trials studying Vitiligo
107 Patients Enrolled for Vitiligo
Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
62 Total Patients Enrolled
3 Trials studying Vitiligo
62 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo
2013. "Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01766609.
All > Vitiligo
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top